{"id":"darzalex-faspro-daratumumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daratumumab targets CD38, a surface antigen highly expressed on multiple myeloma cells. Upon binding, it induces cell death through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Darzalex Faspro is a subcutaneous formulation designed for faster administration compared to intravenous daratumumab.","oneSentence":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:45.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"},{"name":"Light chain multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07222761","phase":"PHASE3","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-01-02","conditions":"Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":915},{"nctId":"NCT07477587","phase":"PHASE1","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-27","conditions":"Multiple Myeloma (MM)","enrollment":258},{"nctId":"NCT07393282","phase":"PHASE3","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-25","conditions":"High Risk Smoldering Multiple Myeloma (HR-SMM)","enrollment":270},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT04270175","phase":"PHASE2","title":"Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-04-14","conditions":"Amyloid, AL Amyloidosis, Refractory AL Amyloidosis","enrollment":15},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT04824794","phase":"PHASE1, PHASE2","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","status":"TERMINATED","sponsor":"Genmab","startDate":"2021-03-09","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)","enrollment":130},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT05182073","phase":"PHASE1","title":"FT576 in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2021-11-10","conditions":"Multiple Myeloma, Myeloma","enrollment":31},{"nctId":"NCT05511428","phase":"PHASE4","title":"Home Based Daratumumab Administration for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-11-08","conditions":"Plasma Cell Myeloma","enrollment":20},{"nctId":"NCT07110844","phase":"PHASE2","title":"Teclistamab-Daratumumab in AL Amyloidosis","status":"RECRUITING","sponsor":"Suzanne Lentzsch, MD","startDate":"2025-11-07","conditions":"Amyloid Light-chain Amyloidosis","enrollment":25},{"nctId":"NCT05300451","phase":"PHASE2","title":"Daratumumab in HLA Desensitization Prior to Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Barry A. Boilson","startDate":"2022-03-31","conditions":"Cardiac Transplant","enrollment":10},{"nctId":"NCT03590652","phase":"PHASE2","title":"Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2018-10-17","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":23},{"nctId":"NCT04302324","phase":"PHASE2","title":"A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-10-28","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma","enrollment":9},{"nctId":"NCT06046287","phase":"PHASE2","title":"Daratumumab for Polyneuropathy Associated With MGUS","status":"WITHDRAWN","sponsor":"Georgetown University","startDate":"2025-09-26","conditions":"Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance","enrollment":""},{"nctId":"NCT06398457","phase":"EARLY_PHASE1","title":"Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-09-19","conditions":"Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML)","enrollment":8},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT06952478","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-08-12","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":486},{"nctId":"NCT06015724","phase":"PHASE2","title":"Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2024-01-31","conditions":"Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer","enrollment":54},{"nctId":"NCT04975997","phase":"PHASE3","title":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2022-06-23","conditions":"Multiple Myeloma","enrollment":864},{"nctId":"NCT04775550","phase":"PHASE2","title":"DARA RVD For High Risk SMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2021-03-08","conditions":"High-risk Smoldering Multiple Myeloma, Multiple Myeloma","enrollment":61},{"nctId":"NCT05561387","phase":"PHASE3","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-10-12","conditions":"Plasma Cell Myeloma","enrollment":510},{"nctId":"NCT06371534","phase":"PHASE1","title":"A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-04-12","conditions":"Tumor","enrollment":228},{"nctId":"NCT06107738","phase":"PHASE2","title":"Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma","status":"RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT06742138","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-01","conditions":"Multiple Myeloma","enrollment":284},{"nctId":"NCT04956302","phase":"PHASE1","title":"Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Abdullah Khan","startDate":"2021-09-27","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":1},{"nctId":"NCT06232707","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2024-05-03","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT06376214","phase":"NA","title":"Daratumumab for Patients With Light Chain Amyloidosis","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2023-01-01","conditions":"Light Chain (AL) Amyloidosis","enrollment":100},{"nctId":"NCT04136756","phase":"PHASE1","title":"NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2019-10-07","conditions":"Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT04649060","phase":"PHASE3","title":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2020-12-21","conditions":"Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma","enrollment":54}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"OFF LABEL USE"},{"count":8,"reaction":"RASH"},{"count":6,"reaction":"DIARRHOEA"},{"count":5,"reaction":"FATIGUE"},{"count":4,"reaction":"NEUTROPENIA"},{"count":4,"reaction":"PLATELET COUNT DECREASED"},{"count":3,"reaction":"ABDOMINAL PAIN UPPER"},{"count":3,"reaction":"ASTHENIA"},{"count":3,"reaction":"DIZZINESS"},{"count":3,"reaction":"FALL"}],"_approvalHistory":[],"publicationCount":2407,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Darzalex Faspro(Daratumumab)","genericName":"Darzalex Faspro(Daratumumab)","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Light chain multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}